(TSX:COPR),(OTC US:CPPMF),(Other OTC:CPPMF),(Boerse Frankfurt – Freiverkehr:9I3), VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), is pleased to announce results from recent geological mapping and channel sampling at Zone 1 within the Nioc target area, which continue to confirm the presence of […]

(NASDAQ:SLNO), REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT(TM)

(NASDAQ:STSS),(NASDAQ:STSSW), NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (“STSS” or the “Company”) (NASDAQ: STSS), a medical device company implementing a Solana-based digital asset treasury strategy, today announced the expansion of its relationship with Coinbase Institutional, a leading provider of custody, prime brokerage, derivatives, staking, and trading services, through the launch of

(NasdaqGM:SKYE), CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety profile. CBeyond Phase 2a topline results to 52 weeks including 13-week off-therapy follow-up period expected in Q3 2026. Phase 2b (CBeyond 2) plan to

(NASDAQ:RLMD), FDA written feedback supports: – a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS – a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD,

(TSX-V:NEXG),(OTC US:NXGCF),(Other OTC:NXGCF), TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company“) is pleased to outline the Company's key milestones and achievements from the past year as it looks towards numerous significant catalysts for 2026. Kevin Bullock, President and CEO, stated: “2025 was the first year

(TSX-V:EMO),(OTC US:EMOTF),(Other OTC:EMOTF),(Frankfurt:LLJA), TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides a corporate update highlighting progress on strategic priorities for its exploration and development plans in Spain. Management expects 2026 will be a pivotal year in the evolution and growth of Emerita.

(NASDAQ:BTAI), Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI(R) in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI(R) this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE

(NasdaqGM:NRIX), Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrutideg into autoimmune and inflammatory indications, targeting IND submission in 2026 with a new tablet formulation Advance a growing portfolio of partnered inflammation and

(NASDAQ:ANNX), Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barre Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502,